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See Article, pages 890–897Hepatocellular carcinoma (HCC) is a highly preva-
lent and lethal cancer type being the third leading cause
of cancer-related death worldwide [1]. More than 80% of
cases occur in developing countries particularly in East-
ern Asia and sub-Saharan Africa mainly due to chronic
infection with hepatitis B virus (HBV) [1,2]. Hence,
HBV is the most common cause of HCC in the world.
Although population-based universal infant vaccination
is shown to be eﬀective in preventing new neonatal HBV
infection and related HCC [3], there are still over 350
million individuals with chronic infection, and the prev-
alence reaches 10–20% of the population in the endemic
areas. Once chronic infection is established, complete
eradication of the virus is still not possible, and these
patients are facing the risk of HCC development [4].
HCC usually develops on a background of chronic
liver damage, i.e., sustained hepatic inﬂammation,
regeneration, and ﬁbrogenesis, owing to hepatitis virus
infection, alcohol abuse, metabolic disorders, or expo-
sure to environmental carcinogens [2]. In fact, cirrhosis
is observed in 80% of HCC patients. These risk factors
are thought to indirectly promote HCC development
by generating a carcinogenic microenvironment in the
liver, known as the “ﬁeld eﬀect”, which is assumed to0168-8278/$36.00  2009 European Association for the Study of the Liver.
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virus.cause accumulated genetic hits inducing cellular trans-
formation [2].
However, in contrast to hepatitis C and other risk
factors, it is known that HBV-related HCC is less asso-
ciated with the presence of cirrhosis, and this trend
becomes more obvious in younger patients whose dura-
tion of infection is not long enough to develop full-
blown cirrhosis [1,2,5]. This observation has prompted
the suggestion that HBV itself has direct carcinogenic
potential, and studies have shown that HBV might
directly activate oncogenic signaling: cis-activation
through integration of viral genetic material into host
cellular genomic DNA and trans-activation by viral
products such as HBx protein [2,5–7]. Other lines of evi-
dence suggest that increased risk of HCC is associated
with certain HBV genotypes, e.g., genotype C in Asian
population [8,9] and genotype F in the Alaskan popula-
tion [10]. In addition, precore and basal core promoter
mutations in the HBV genome have been reported as
risk factors of HCC development [9,11–13]. These ﬁnd-
ings suggest that there is a certain variation in the car-
cinogenic potential according to the viral strains.
Consistent with the hypothesis of direct carcino-
genic eﬀect of HBV, accumulating evidence has
shown that a high serum HBV DNA level, indicative
of increased viral replication, is a risk factor for de novo
HCC development in HBV carriers irrespective of hepa-
titis activity [14–16]. In addition, a recent study sug-
gested that prolonged suppression of HBV replication
with nucleoside or nucleotide analogs may reduce the
risk of HBV-related HCC development [17], suggesting
that antiviral treatment is a promising strategy to pre-
vent hepatocarcinogenesis.Published by Elsevier B.V. All rights reserved.
Y. Hoshida / Journal of Hepatology 51 (2009) 842–844 843Localized HCC tumors can be subjected to poten-
tially curative treatments such as surgical resection and
percutaneous ablation. However, even after such radical
therapies, more than 70% of patients have recurrence at
5 years, which still limits survival of the patients [1]. It is
known that there are two distinct types of HCC recur-
rence: tumors grown from dissemination of the primary
tumor and de novo tumors arising from the “ﬁeld eﬀect”
in diseased liver [1,18–20]. That is, the latter is clonally
independent from the primary tumor. Discrimination
of these types of recurrence is clinically important
because the biological basis producing each recurrence
is diﬀerent and the following therapeutic intervention
should be considered accordingly [21]. However, it is dif-
ﬁcult to examine the clonal diﬀerence from a practical
point of view in the clinical setting because of the lack
of reliable and clinically applicable markers.
Imamura et al. proposed a convenient framework to
clinically diﬀerentiate each type of recurrence as “early”
or “late” recurrence based on a cut-oﬀ of 2 years after
surgery [22]. This framework has made it possible to
assess risk factors for each type of recurrence [18,23].
Early recurrence, which appears within 2 years after sur-
gery, is associated with tumor-related factors including
the presence of vascular invasion and additional tumor
sites besides the primary lesion (satellite lesion), which
is consistent with the notion that this type of recurrence
is tumor dissemination as a consequence of malignant
characteristic of the primary tumor. On the other hand,
late recurrence, which appears more than 2 years after
surgery, is considered to be associated with the severity
of hepatic inﬂammation and liver damage closely linked
to the “ﬁeld eﬀect”.
With the successful implementation of HCC surveil-
lance programs, increasing number of HCC tumors
are diagnosed at an early stage, where the tumor has less
likelihood of dissemination and thus removed more
eﬀectively without residual tumor cells [24]. This means
that more patients avoid the risk of early recurrence and
thus survive longer enough to acquire late recurrence.
This shift of recurrence pattern highlights increasing
necessity to focus on late recurrence, which cannot be
treated with early detection and resection of the primary
tumor.
In theory, late recurrence is assumed to arise from the
same biology associated with the initial HCC develop-
ment in cirrhosis [19], and thus in HBV-related HCC,
both of the direct carcinogenic eﬀect of HBV and the
“ﬁeld eﬀect” are assumed to be responsible for late
recurrence. Recently, Kim et al. reported that persistent
viremia is associated with disease-free survival after 12
months of surgery, suggesting its association with late
recurrence [25]. In this issue of the Journal, Wu et al.
evaluated clinical variables together with HBV-related
factors including viral load, genotype, and recurrent
mutations, for their prognostic implication with respectto early and late recurrence in 193 HBV-related HCC
patients [26]. During the median follow-up of 5 years,
134 patients (69%) had HCC recurrence, which is com-
parable to the ﬁgures in the literature [18]. Consistent
with the notion of the pattern of HCC recurrence, the
study clearly showed that tumor-related factors (micro-
vascular invasion, positive cut margin, and high serum
AFP level) were associated with the risk of early recur-
rence, whereas liver inﬂammation/damage-related fac-
tors (histological inﬂammation and ICG-15 retention
rate) were independently associated with the risk of late
recurrence [26]. Of note, high HBV viral load was found
to be associated with the risk of late, but not early,
recurrence. The frequency of genotype C in HCC
patients was higher compared to HBV carriers and
correlated with high HBV viral load and more severe
histological inﬂammation, consistent with previous
observations [8,9]. The recurrent mutations were also
correlated with genotype C to some extent. However,
the viral load was the only signiﬁcant variable indepen-
dently associated with late recurrence, probably because
the high HBV DNA level is the most functional measure
reﬂecting the exposure to the direct carcinogenic eﬀect of
HBV. In the multivariate analysis, tumor multinodular-
ity appeared to be associated with both early and late
recurrences, which assumingly indicates the presence of
satellite tumors due to the dissemination as well as the
“ﬁeld eﬀect”-related multicentric metachronous tumors.
In conclusion, these ﬁndings conﬁrmed that late
recurrence mostly corresponds to de novo carcinogenesis
associated with HBV viremia as well as the “ﬁeld eﬀect”
in HBV-related HCC. This may support prioritized use
of anti-HBV treatment as adjuvant therapy after the
resection or ablation of HCC for the patients with a high
HBV DNA level to prevent late recurrence. This sce-
nario may prompt the design of more powered clinical
trials compared to the setting of chemoprevention tar-
geting cirrhosis to prevent initial HCC development,
given that the incidence rate of recurrence is higher than
that of initial HCC development [27]. Furthermore,
investigation of the molecular mechanism of the direct
carcinogenic eﬀect of HBV may help clarify additional
therapeutic targets in terms of HCC prevention. Cur-
rently available evidence, mostly obtained from PCR-
based assays with limited scale, have identiﬁed a handful
of the genomic integrations potentially aﬀecting func-
tion of genes, e.g., cyclin A and telomerase reverse trans-
criptase, in a sporadic manner [6,7]. Recently emerging
genomics technology like high-throughput sequencing
[28,29] may provide a more comprehensive view of crit-
ical recurrent oncogenic integration events. Combina-
tion of the new sequencing assay with chromatin
immunoprecipitation (ChIP-Seq) [30], may help to iden-
tify oncogenic transactivation by HBV proteins to
obtain complementary information of the direct carcin-
ogenic eﬀect caused by HBV.
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